Hikma Pharmaceuticals Regulatory News (HIK)

For filings with the FCA include the annex

For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Hikma Pharmaceuticals PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

ü

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Boehringer Ingelheim Corporation;Boehringer Ingelheim USA Corporation;Boehringer Ingelheim Auslandsbeteiligungs GmbH;

Boehringer Ingelheim International GmbH;

Boehringer Ingelheim Verwaltungs GmbH;

Dr. Karl Thomae GmbH;

C.H. Boehringer Sohn AG & Co. KG

4. Full name of shareholder(s)  (if different from 3.):iv

Boehringer Ingelheim Corporation

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

29 February 2016

6. Date on which issuer notified:

29 February 2016

7. Threshold(s) that is/are crossed orreached: vi, vii

16%

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Indirect

Direct xi

Indirect xii

Direct

Indirect

GB00B0LCW083

0

0

40,000,000

40,000,000

0

16.67%

0

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

40,000,000

16.67%

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

Boehringer Ingelheim Corporation has the following parent undertakings:

Boehringer Ingelheim USA Corporation, a Delaware corporation (wholly owns the voting shares in Boehringer Ingelheim Corporation).

Boehringer Ingelheim Auslandsbeteiligungs GmbH, a German company with limited liability (wholly owns Boehringer Ingelheim USA Corporation).

Boehringer Ingelheim International GmbH, a German company with limited liability (wholly owns Boehringer Ingelheim Auslandsbeteiligungs GmbH).

Boehringer Ingelheim Verwaltungs GmbH, a German company with limited liability (wholly owns Boehringer Ingelheim International GmbH).

Dr. Karl Thomae GmbH, a German company with limited liability (wholly owns Boehringer Ingelheim Verwaltungs GmbH).

C.H. Boehringer Sohn AG & Co. KG, a German limited partnership (wholly owns Dr. Karl Thomae GmbH).

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will acquire:

12. Date on which proxy holder will acquire voting rights:

13. Additional information:

None

14. Contact name:

Stephan Bach (Corporate Treasury)

Eric Humbert (Corporate Treasury)

15. Contact telephone number:

Stephan Bach: +49 (6132) 77-3032Eric Humbert: +49 (6132) 77-90717